Oligonucleotide Delivery System Market Size, Share & Trends Analysis Distribution by Delivery System (Conjugation-Based Delivery Systems (GALNAc Conjugation, Ligand Conjugation, Antibody Conjugation, Targeting Moiety Conjugation), Nanoparticle-Based Delivery Systems (Lipid Nanoparticles (LNPs), Peptide Nanoparticles), Viral Vector-Based Delivery Systems (Adeno-associated Virus (AAV) Vectors, AAV9, Lentiviral Vectors, Others), Exosome-Based Delivery Systems, Liposomes, Others), Disease Indication and Segment Forecasts, 2024-2031

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Oligonucleotide Delivery System Market Snapshot Chapter 4. Global Oligonucleotide Delivery System Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis 4.6. Porter's Five Forces Analysis 4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031 4.8. Global Oligonucleotide Delivery System Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031 4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023) 4.10. Use/impact of AI on Oligonucleotide Delivery System Industry Trends Chapter 5. Oligonucleotide Delivery System Market Segmentation 1: By Delivery System, Estimates & Trend Analysis 5.1. Market Share by Delivery System, 2023 & 2031 5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Delivery System: 5.2.1. Conjugation-Based Delivery Systems 5.2.1.1. GALNAc Conjugation 5.2.1.2. Ligand Conjugation 5.2.1.3. Antibody Conjugation 5.2.1.4. Targeting Moiety Conjugation 5.2.2. Nanoparticle-Based Delivery Systems 5.2.2.1. Lipid Nanoparticles (LNPs) 5.2.2.2. Peptide Nanoparticles 5.2.3. Viral Vector-Based Delivery Systems 5.2.3.1. Adeno-associated Virus (AAV) Vectors 5.2.3.2. AAV9 5.2.3.3. Lentiviral Vectors 5.2.3.4. Others 5.2.4. Exosome-Based Delivery Systems 5.2.5. Liposomes 5.2.6. Others Chapter 6. Oligonucleotide Delivery System Market Segmentation 2: By Disease Indication, Estimates & Trend Analysis 6.1. Market Share by Disease Indication, 2023 & 2031 6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Disease Indications: 6.2.1. Genetic Disorders 6.2.2. Infectious Diseases 6.2.3. Oncology 6.2.4. Neurological Disorders 6.2.5. Others (Autoimmune Diseases, Metabolic Disorders, etc.) Chapter 7. Oligonucleotide Delivery System Market Segmentation 3: Regional Estimates & Trend Analysis 7.1. Global Oligonucleotide Delivery System Market, Regional Snapshot 2023 & 2031 7.2. North America 7.2.1. North America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031 7.2.1.1. US 7.2.1.2. Canada 7.2.2. North America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031 7.2.3. North America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031 7.3. Europe 7.3.1. Europe Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031 7.3.1.1. Germany 7.3.1.2. U.K. 7.3.1.3. France 7.3.1.4. Italy 7.3.1.5. Spain 7.3.1.6. Rest of Europe 7.3.2. Europe Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031 7.3.3. Europe Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031 7.4. Asia Pacific 7.4.1. Asia Pacific Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031 7.4.1.1. India 7.4.1.2. China 7.4.1.3. Japan 7.4.1.4. Australia 7.4.1.5. South Korea 7.4.1.6. Hong Kong 7.4.1.7. Southeast Asia 7.4.1.8. Rest of Asia Pacific 7.4.2. Asia Pacific Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031 7.4.3. Asia Pacific Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031 7.5. Latin America 7.5.1. Latin America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031 7.5.1.1. Brazil 7.5.1.2. Mexico 7.5.1.3. Rest of Latin America 7.5.2. Latin America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031 7.5.3. Latin America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031 7.6. Middle East & Africa 7.6.1. Middle East & Africa Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031 7.6.1.1. GCC Countries 7.6.1.2. Israel 7.6.1.3. South Africa 7.6.1.4. Rest of Middle East and Africa 7.6.2. Middle East & Africa Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031 7.6.3. Middle East & Africa Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031 Chapter 8. Competitive Landscape 8.1. Major Mergers and Acquisitions/Strategic Alliances 8.2. Company Profiles 8.2.1. Biogen 8.2.1.1. Business Overview 8.2.1.2. Key Product/Service Offerings 8.2.1.3. Financial Performance 8.2.1.4. Geographical Presence 8.2.1.5. Recent Developments with Business Strategy 8.2.2. Sarepta Therapeutics, Inc. 8.2.3. Jazz Pharmaceuticals plc 8.2.4. Ionis Pharmaceuticals, Inc. 8.2.5. Nippon Shinyaku Co., Ltd. 8.2.6. AstraZeneca 8.2.7. Alnylam Pharmaceuticals, Inc. 8.2.8. Novartis AG 8.2.9. Dicerna Pharmaceuticals, Inc. (Novo Nordisk) 8.2.10. IVERIC bio, Inc. (Astellas Pharma Inc.) 8.2.11. Elsie Biotechnologies (GSK) 8.2.12. Other Prominent Players